Daniel M. Hinds
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daniel M. Hinds has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Deborah R. Liptzin
Department of Pediatrics, Division of Pediatric Pulmonary and Sleep Medicine, School of Medicine University of Washington Seattle Washington USA
3 shared publicationsJason P. Weinman
Section of Pediatric Radiology, Department of Radiology University of Colorado Anschutz Medical Campus Aurora Colorado USA
3 shared publicationsCarl W. White
Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado
2 shared publications- Heidi J. Nick
Department of Pediatrics, National Jewish Health, Denver, CO 80206, USA
2 shared publications John T. Brinton
Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado
2 shared publicationsKimberly A. Dannull
Section of Pediatric Radiology, Department of Radiology University of Colorado Anschutz Medical Campus Aurora Colorado USA
2 shared publications
Latest Publications
- Open Access
- 31 May 2024
- Published by Wiley in Pediatric Pulmonology
- Vol. 59 (10) , 2428-2434
Pediatric Pulmonology 2023 year in review: Rare and diffuse lung disease
The field of pediatric rare and diffuse lung disease continues its maturation as research advances the understanding of diagnosis and treatment of children's interstitial lung disease, noncystic fibrosis bronchiectasis, and primary ciliary dyskinesia. The rarity and breadth of these conditions make them challenging to study, yet we continue to make progress in our understanding of pathophysiology, genotype/phenotype relationships, and treatment. Papers published on these topics in Pediatric Pulmonology and other journals in 2023 describe the power of multicenter cooperation and patient registries, enhance our understanding of pathophysiology and genotype/phenotype relationships, and report progress in treatments. In this review, we hope to increase awareness and knowledge of these conditions and to inspire future research.
- 31 May 2024
- Published by Wiley in Pediatric Pulmonology
- Vol. 59 (10) , 2428-2434
Open AccessPediatric Pulmonology 2023 year in review: Rare and diffuse lung disease
The field of pediatric rare and diffuse lung disease continues its maturation as research advances the understanding of diagnosis and treatment of children's interstitial lung disease, noncystic fibrosis bronchiectasis, and primary ciliary dyskinesia. The rarity and breadth of these conditions make them challenging to study, yet we continue to make progress in our understanding of pathophysiology, genotype/phenotype relationships, and treatment. Papers published on these topics in Pediatric Pulmonology and other journals in 2023 describe the power of multicenter cooperation and patient registries, enhance our understanding of pathophysiology and genotype/phenotype relationships, and report progress in treatments. In this review, we hope to increase awareness and knowledge of these conditions and to inspire future research.
- 30 August 2022
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 323 (5) , L525-L535
Acute vaping in a golden Syrian hamster causes inflammatory response transcriptomic changes
E-cigarette vaping is a major aspect of nicotine consumption, especially for children and young adults. Although it is branded as a safer alternative to cigarette smoking, murine and rat models of subacute and chronic e-cigarette vaping exposure have shown many proinflammatory changes in the respiratory tract. An acute vaping exposure paradigm has not been demonstrated in the golden Syrian hamster, and the hamster is a readily available small animal model that has the unique benefit of becoming infected with and transmitting respiratory viruses, including SARS-CoV-2, without genetic alteration of the animal or virus. Using a 2-day, whole body vaping exposure protocol in male golden Syrian hamsters, we evaluated serum cotinine, bronchoalveolar lavage cells, lung, and nasal histopathology, and gene expression in the nasopharynx and lung through reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Depending on the presence of nonnormality or outliers, statistical analysis was performed by ANOVA or Kruskal–Wallis tests. For tests that were statistically significant ( P < 0.05), post hoc Tukey–Kramer and Dunn’s tests, respectively, were performed to make pairwise comparisons between groups. In nasal tissue, RT-qPCR analysis revealed nicotine-dependent increases in gene expression associated with type 1 inflammation ( CCL-5 and CXCL-10), fibrosis [transforming growth factor-β ( TGF-β)], nicotine-independent increase oxidative stress response ( SOD-2), and a nicotine-independent decrease in vasculogenesis/angiogenesis (VEGF-A). In the lung, nicotine-dependent increases in the expression of genes involved in the renin-angiotensin pathway [angiotensin-converting enzyme ( ACE), ACE2], coagulation ( tissue factor, Serpine-1), extracellular matrix remodeling ( MMP-2, MMP-9), type 1 inflammation ( IL-1β, TNF-α, and CXCL-10), fibrosis ( TGF-β and Serpine-1), oxidative stress response ( SOD-2), neutrophil extracellular traps release ( ELANE), and vasculogenesis and angiogenesis ( VEGF-A) were identified. To our knowledge, this is the first demonstration that the Syrian hamster is a viable model of e-cigarette vaping. In addition, this is the first report that e-cigarette vaping with nicotine can increase tissue factor gene expression in the lung. Our results show that even an acute exposure to e-cigarette vaping causes significant upregulation of mRNAs in the respiratory tract from pathways involving the renin-angiotensin system, coagulation, extracellular matrix remodeling, type 1 inflammation, fibrosis, oxidative stress response, neutrophil extracellular trap release (NETosis), vasculogenesis, and angiogenesis.
- 30 August 2022
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 323 (5) , L525-L535
Acute vaping in a golden Syrian hamster causes inflammatory response transcriptomic changes
E-cigarette vaping is a major aspect of nicotine consumption, especially for children and young adults. Although it is branded as a safer alternative to cigarette smoking, murine and rat models of subacute and chronic e-cigarette vaping exposure have shown many proinflammatory changes in the respiratory tract. An acute vaping exposure paradigm has not been demonstrated in the golden Syrian hamster, and the hamster is a readily available small animal model that has the unique benefit of becoming infected with and transmitting respiratory viruses, including SARS-CoV-2, without genetic alteration of the animal or virus. Using a 2-day, whole body vaping exposure protocol in male golden Syrian hamsters, we evaluated serum cotinine, bronchoalveolar lavage cells, lung, and nasal histopathology, and gene expression in the nasopharynx and lung through reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Depending on the presence of nonnormality or outliers, statistical analysis was performed by ANOVA or Kruskal–Wallis tests. For tests that were statistically significant ( P < 0.05), post hoc Tukey–Kramer and Dunn’s tests, respectively, were performed to make pairwise comparisons between groups. In nasal tissue, RT-qPCR analysis revealed nicotine-dependent increases in gene expression associated with type 1 inflammation ( CCL-5 and CXCL-10), fibrosis [transforming growth factor-β ( TGF-β)], nicotine-independent increase oxidative stress response ( SOD-2), and a nicotine-independent decrease in vasculogenesis/angiogenesis (VEGF-A). In the lung, nicotine-dependent increases in the expression of genes involved in the renin-angiotensin pathway [angiotensin-converting enzyme ( ACE), ACE2], coagulation ( tissue factor, Serpine-1), extracellular matrix remodeling ( MMP-2, MMP-9), type 1 inflammation ( IL-1β, TNF-α, and CXCL-10), fibrosis ( TGF-β and Serpine-1), oxidative stress response ( SOD-2), neutrophil extracellular traps release ( ELANE), and vasculogenesis and angiogenesis ( VEGF-A) were identified. To our knowledge, this is the first demonstration that the Syrian hamster is a viable model of e-cigarette vaping. In addition, this is the first report that e-cigarette vaping with nicotine can increase tissue factor gene expression in the lung. Our results show that even an acute exposure to e-cigarette vaping causes significant upregulation of mRNAs in the respiratory tract from pathways involving the renin-angiotensin system, coagulation, extracellular matrix remodeling, type 1 inflammation, fibrosis, oxidative stress response, neutrophil extracellular trap release (NETosis), vasculogenesis, and angiogenesis.
- Open Access
Acute Vaping of a golden Syrian Hamster is Feasible and Leads to Nicotine-Dependent Respiratory Tract Inflammation
Introduction: E-cigarette vaping has become a major portion of nicotine consumption, especially for children and young adults. Although it is branded as a safer alternative to cigarette smoking, murine and rat models of sub-acute and chronic e-cigarette vaping exposure have shown many pro-inflammatory changes in the respiratory tract. An acute vaping exposure paradigm has not been demonstrated in the golden Syrian hamster, and the hamster is a readily available small animal model that has the unique benefit of becoming infected with and transmitting SARS-CoV-2 without genetic alteration to the animal or virus. Methods: Using a two-day, whole-body vaping exposure protocol in male golden Syrian hamsters, we evaluated serum cotinine, bronchoalveolar lavage cells, lung and nasal histopathology, and gene expression in the nasopharynx and lung through RT-qPCR. Depending on the presence of nonnormality or outliers, statistical analysis was performed by ANOVA or Kruskal-Wallis tests. For tests that were statistically significant (p-value <0.05), post-hoc Tukey-Kramer and Dunn’s tests, respectively, were performed to make pairwise comparisons between groups. Results: In nasal tissue, RT-qPCR analysis revealed nicotine-dependent increases in genes associated with type 1 inflammation (CCL-5 and CXCL-10), fibrosis (TGF-β), and a nicotine-independent decrease in the vasculogenesis/angiogenesis gene VEGF-A. In the lung, nicotine-dependent increases in the expression of genes involved in the renin-angiotensin pathway (ACE, ACE2), coagulation (tissue factor, Serpine-1), extracellular matrix remodeling (MMP-2, MMP-9), type 1 inflammation (IL-1β, TNF-α, and CXCL-10), fibrosis (TGF-β and Serpine-1), oxidative stress response (SOD-2), neutrophil extracellular traps release (ELANE), and vasculogenesis and angiogenesis (VEGF-A) were identified. Conclusion: To our knowledge, this is the first demonstration that the Syrian hamster is a viable model of e-cig induced inhalational injury. In addition, this is the first report that e-cig vaping with nicotine can increase tissue factor gene expression in the lung. Our results show that even an acute exposure to e-cigarette vaping causes significant upregulation in the respiratory tract of pathways involving the renin-angiotensin system, coagulation, extracellular matrix remodeling, type 1 inflammation, fibrosis, oxidative stress response, NETosis, vasculogenesis, and angiogenesis.
Open AccessAcute Vaping of a golden Syrian Hamster is Feasible and Leads to Nicotine-Dependent Respiratory Tract Inflammation
Introduction: E-cigarette vaping has become a major portion of nicotine consumption, especially for children and young adults. Although it is branded as a safer alternative to cigarette smoking, murine and rat models of sub-acute and chronic e-cigarette vaping exposure have shown many pro-inflammatory changes in the respiratory tract. An acute vaping exposure paradigm has not been demonstrated in the golden Syrian hamster, and the hamster is a readily available small animal model that has the unique benefit of becoming infected with and transmitting SARS-CoV-2 without genetic alteration to the animal or virus. Methods: Using a two-day, whole-body vaping exposure protocol in male golden Syrian hamsters, we evaluated serum cotinine, bronchoalveolar lavage cells, lung and nasal histopathology, and gene expression in the nasopharynx and lung through RT-qPCR. Depending on the presence of nonnormality or outliers, statistical analysis was performed by ANOVA or Kruskal-Wallis tests. For tests that were statistically significant (p-value <0.05), post-hoc Tukey-Kramer and Dunn’s tests, respectively, were performed to make pairwise comparisons between groups. Results: In nasal tissue, RT-qPCR analysis revealed nicotine-dependent increases in genes associated with type 1 inflammation (CCL-5 and CXCL-10), fibrosis (TGF-β), and a nicotine-independent decrease in the vasculogenesis/angiogenesis gene VEGF-A. In the lung, nicotine-dependent increases in the expression of genes involved in the renin-angiotensin pathway (ACE, ACE2), coagulation (tissue factor, Serpine-1), extracellular matrix remodeling (MMP-2, MMP-9), type 1 inflammation (IL-1β, TNF-α, and CXCL-10), fibrosis (TGF-β and Serpine-1), oxidative stress response (SOD-2), neutrophil extracellular traps release (ELANE), and vasculogenesis and angiogenesis (VEGF-A) were identified. Conclusion: To our knowledge, this is the first demonstration that the Syrian hamster is a viable model of e-cig induced inhalational injury. In addition, this is the first report that e-cig vaping with nicotine can increase tissue factor gene expression in the lung. Our results show that even an acute exposure to e-cigarette vaping causes significant upregulation in the respiratory tract of pathways involving the renin-angiotensin system, coagulation, extracellular matrix remodeling, type 1 inflammation, fibrosis, oxidative stress response, NETosis, vasculogenesis, and angiogenesis.
- 29 November 2021
- Published by Wiley in Pediatric Pulmonology
- Vol. 56 (12)
Cover Image, Volume 56, Number 12, December 2021
- 29 November 2021
- Published by Wiley in Pediatric Pulmonology
- Vol. 56 (12)
Cover Image, Volume 56, Number 12, December 2021
- 22 September 2021
- Published by Wiley in Pediatric Pulmonology
- Vol. 56 (12) , 4057-4059
Vaping and diffuse alveolar hemorrhage: All EVALI is not created equal
E‐cigarette, or vaping product, use associated lung injury (EVALI) refers to respiratory illness in patients with recent vaping and no signs of infection or underlying illness. EVALI can cause severe acute respiratory distress syndrome and death. A spectrum of diagnoses can fit the description of EVALI since it relies heavily on nonspecific, radiographic findings. We present a rare case of EVALI in which a patient with a history of vaping presented with acute hypoxemia and was diagnosed with diffuse alveolar hemorrhage (DAH). The mechanism of injury of DAH due to vaping is unknown, and further research into the topic is required.
- 22 September 2021
- Published by Wiley in Pediatric Pulmonology
- Vol. 56 (12) , 4057-4059
Vaping and diffuse alveolar hemorrhage: All EVALI is not created equal
E‐cigarette, or vaping product, use associated lung injury (EVALI) refers to respiratory illness in patients with recent vaping and no signs of infection or underlying illness. EVALI can cause severe acute respiratory distress syndrome and death. A spectrum of diagnoses can fit the description of EVALI since it relies heavily on nonspecific, radiographic findings. We present a rare case of EVALI in which a patient with a history of vaping presented with acute hypoxemia and was diagnosed with diffuse alveolar hemorrhage (DAH). The mechanism of injury of DAH due to vaping is unknown, and further research into the topic is required.
- 1 February 2021
- Published by Wiley in Pediatric Pulmonology
- Vol. 56 (6) , 1789-1792
Pulmonary eosinophilic vasculitis with granulomas and benralizumab in children
- 1 February 2021
- Published by Wiley in Pediatric Pulmonology
- Vol. 56 (6) , 1789-1792
Pulmonary eosinophilic vasculitis with granulomas and benralizumab in children
- 24 September 2020
- Published by Wiley in Pediatric Pulmonology
- Vol. 55 (12) , 3400-3406
Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers
Introduction: Oral antibiotics are frequently prescribed for outpatient pulmonary exacerbations (PEx) in children with cystic fibrosis (CF). This study aimed to characterize oral antibiotic use for PEx and treatment outcomes at two large US CF centers.Methods: Retrospective, descriptive study of oral antibiotic prescribing practices among children with CF ages 6–17 years over 1 year. The care setting for antibiotic initiation (clinic or phone encounter) was determined and outcomes were compared.Results: A total of 763 oral antibiotic courses were prescribed to 312 patients aged 6–17 years (77% of 403 eligible patients) with a median of two courses per year (range: 1–10). Fifty‐eight percent of prescriptions were provided over the phone. Penicillin was the most commonly prescribed antibiotic class (36% of prescriptions) but differences in antibiotic class prescriptions were noted between the two centers. Hospitalizations occurred within 3 months following 19% of oral antibiotic courses. Forced expiratory volume in 1 s (FEV1) recovered to within 90% of prior baseline within 6 months in 87% of encounters; the mean (SD) % recovery was 99.6% (12.1%) of baseline. Outcomes did not differ between phone and clinic prescriptions.Conclusions: Phone prescriptions, commonly excluded in studies of PEx, made up more than half of all oral antibiotic courses. Heterogeneity in prescribing patterns was observed between the two centers. Most patients had improvement in FEV1 returning to near their prior baseline, but hospitalizations occurred in one‐fifth following oral antibiotic treatment. Efforts to optimize PEx treatment must consider care that occurs over the phone; this is particularly important as the use of telemedicine increases.
- 24 September 2020
- Published by Wiley in Pediatric Pulmonology
- Vol. 55 (12) , 3400-3406
Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers
Introduction: Oral antibiotics are frequently prescribed for outpatient pulmonary exacerbations (PEx) in children with cystic fibrosis (CF). This study aimed to characterize oral antibiotic use for PEx and treatment outcomes at two large US CF centers.Methods: Retrospective, descriptive study of oral antibiotic prescribing practices among children with CF ages 6–17 years over 1 year. The care setting for antibiotic initiation (clinic or phone encounter) was determined and outcomes were compared.Results: A total of 763 oral antibiotic courses were prescribed to 312 patients aged 6–17 years (77% of 403 eligible patients) with a median of two courses per year (range: 1–10). Fifty‐eight percent of prescriptions were provided over the phone. Penicillin was the most commonly prescribed antibiotic class (36% of prescriptions) but differences in antibiotic class prescriptions were noted between the two centers. Hospitalizations occurred within 3 months following 19% of oral antibiotic courses. Forced expiratory volume in 1 s (FEV1) recovered to within 90% of prior baseline within 6 months in 87% of encounters; the mean (SD) % recovery was 99.6% (12.1%) of baseline. Outcomes did not differ between phone and clinic prescriptions.Conclusions: Phone prescriptions, commonly excluded in studies of PEx, made up more than half of all oral antibiotic courses. Heterogeneity in prescribing patterns was observed between the two centers. Most patients had improvement in FEV1 returning to near their prior baseline, but hospitalizations occurred in one‐fifth following oral antibiotic treatment. Efforts to optimize PEx treatment must consider care that occurs over the phone; this is particularly important as the use of telemedicine increases.